HIV

Pharmacists can bridge gaps through education, inclusive care, and streamlined access.

Islatravir in combination with lenacapavir could become the first weekly oral HIV treatment.

Cabotegravir long-acting when used for HIV pre-exposure prophylaxis (PrEP) showed adherence, effectiveness, and improvements in quality of life by those who received the injection.

Pharmacists should be aware of workplace hazards involving sharps and, if necessary, initiate oPEP.

The study findings signal the need for improved equality in PrEP prescribing across various institutions and settings.

These results build off the PURPOSE 1 trial, contributing to the wealth of evidence surrounding lenacapavir’s positive effects in patients with HIV.

Medication therapy management reimbursement can be a driving factor to work toward statin implementation in this patient group.

Cholesterol-lowering agents, like statins, reduced the risk of major adverse cardiovascular events and cardiovascular disease in patients with HIV.

Dolutegravir/lamivudine was non-inferior to bictegravir/emtricitabine/tenofovir alafenamide fumarate, meeting the study’s primary end point.

The experimental drug successfully reduced levels of SIV, the nonhuman primate equivalent of HIV, in the brain.

An extension of a long-acting cabotegravir study shows safety prior to and during pregnancy in cisgender women, with full results being presented at the 2024 International AIDS Conference.

Adherence and efficacy were both higher in patients with HIV who took twice-yearly lenacapavir compared to those on oral preexposure prophylaxis medication.

The shift is intended to maintain uninterrupted access to PrEP, crucial for preventing HIV, and highlights the ongoing efforts to end the HIV epidemic by improving public health outcomes.

Previous studies have shown that individuals living with HIV are at higher risk for heart disease than individuals without HIV

Study investigators hired undercover shoppers, and the results revealed more education is needed on the Syringe Service Program, which provides legal, clean over-the-counter (OTC) needles to whomever seeks them out.

The approval is based on data from Study 5310, evaluating the pharmacokinetics, safety, and efficacy of Biktarvy (Gilead Sciences Inc) in pregnant individuals.

The treatment is indicated for adolescents at least 12 years of age who weigh at least 25 kg without a previous treatment history of antiretroviral therapies.

Rilpivirine (Edurant Ped; Johnson and Johnson) is indicated for the treatment of HIV in combination with other antiretroviral therapies in treatment-naïve pediatric patients.

This grant funding is a part of the company’s 3-year Setting the P.A.C.E. initiative.

The new indication includes individuals with HIV who have suppressed viral loads with known or suspected M184V/I resistance.

Regardless of a pharmacist’s practice site or type, they play an integral role in ensuring the treatment success of patients with HIV.

According to the authors, the findings may have broad implications for understanding recombination and viral evolution within various organisms.

Variations and conditions included in existing state bills, however, limit the effectiveness of this approach.

Investigators also found that those with HIV were more likely to be readmitted to the hospital within 30 days of cardiac surgery.

Pharmacists involvement in HIV care and treatment has been shown to lead to clinically and statistically significant improvements in ART adherence, as well as greater viral load suppression for patients with HIV.

The study results also determined that those who were previously vaccinated against smallpox had a 2.7 times higher immune response than those who were not previously vaccinated.

Because alcohol is a driver of HIV-associated comorbidities, the reduction interventions may improve the health of people with HIV.

Pharmacists play a vital role in HIV care by addressing social determinants of health, managing complex HIV medication regimens, and providing comprehensive patient counseling.

The study authors note that the findings could be significant in future HIV vaccine design and development, as well as new approaches to HIV immunotherapy.

This finding can be a first step toward getting more infants to HIV remission, allowing them to remain off antiretroviral drugs for longer periods.